as of 01-27-2026 10:09am EST
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | IRVING |
| Market Cap: | 8.0B | IPO Year: | 2025 |
| Target Price: | $34.71 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.86 - $42.50 | Next Earning Date: | 02-12-2026 |
| Revenue: | $649,062,000 | Revenue Growth: | 112.02% |
| Revenue Growth (this year): | 77.47% | Revenue Growth (next year): | 35.87% |
See how CAI stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CAI Caris Life Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.